Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.

Saved in:
Bibliographic Details
Main Authors: Zingales,Bianca, Miles,Michael A, Moraes,Carolina B, Luquetti,Alejandro, Guhl,Felipe, Schijman,Alejandro G, Ribeiro,Isabela
Format: Digital revista
Language:English
Published: Instituto Oswaldo Cruz, Ministério da Saúde 2014
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000600828
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0074-02762014000600828
record_format ojs
spelling oai:scielo:S0074-027620140006008282014-10-07Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversityZingales,BiancaMiles,Michael AMoraes,Carolina BLuquetti,AlejandroGuhl,FelipeSchijman,Alejandro GRibeiro,Isabela in vitro drug screening T. cruzi genetic diversity guidelines This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.info:eu-repo/semantics/openAccessInstituto Oswaldo Cruz, Ministério da SaúdeMemórias do Instituto Oswaldo Cruz v.109 n.6 20142014-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000600828en10.1590/0074-0276140156
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Zingales,Bianca
Miles,Michael A
Moraes,Carolina B
Luquetti,Alejandro
Guhl,Felipe
Schijman,Alejandro G
Ribeiro,Isabela
spellingShingle Zingales,Bianca
Miles,Michael A
Moraes,Carolina B
Luquetti,Alejandro
Guhl,Felipe
Schijman,Alejandro G
Ribeiro,Isabela
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
author_facet Zingales,Bianca
Miles,Michael A
Moraes,Carolina B
Luquetti,Alejandro
Guhl,Felipe
Schijman,Alejandro G
Ribeiro,Isabela
author_sort Zingales,Bianca
title Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_short Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_full Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_fullStr Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_full_unstemmed Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_sort drug discovery for chagas disease should consider trypanosoma cruzi strain diversity
description This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
publisher Instituto Oswaldo Cruz, Ministério da Saúde
publishDate 2014
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000600828
work_keys_str_mv AT zingalesbianca drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT milesmichaela drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT moraescarolinab drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT luquettialejandro drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT guhlfelipe drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT schijmanalejandrog drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
AT ribeiroisabela drugdiscoveryforchagasdiseaseshouldconsidertrypanosomacruzistraindiversity
_version_ 1756383784816607232

Similar Items